Bionet Therapeutics (ROCO:7808) Stock Based Compensation: NT$18.9 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7808 Bionet Therapeutics Corp ROCO:7808
20 GF Score
Price NT$33.80
! 2 Warning Signs
View Full Analysis

What is Bionet Therapeutics Stock Based Compensation?

Bionet Therapeutics ROCO:7808 +2.42% 20 Stock Based Compensation is NT$18.9 Mil as of Jun. 2026. GuruFocus rates ROCO:7808 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Bionet Therapeutics's Stock Based Compensation for the six months ended in Jun. 2026 was NT$7.8 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was NT$18.9 Mil.

Bionet Therapeutics Stock Based Compensation Related Terms

Bionet Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Bionet Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics Stock Based Compensation Chart

Bionet Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.00 0.16 3.71 18.69

Bionet Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Stock Based Compensation Get a 7-Day Free Trial 1.25 2.46 7.52 11.17 7.75
ROCO:7808
20GF Score
Bionet Therapeutics Corp ROCO:7808
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionet Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$18.9 Mil.

What does a Stock Based Compensation of NT$18.9 Mil mean?
Bionet Therapeutics (ROCO:7808) has a Stock Based Compensation of NT$18.9 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bionet Therapeutics and its competitors.
Is Bionet Therapeutics' Stock Based Compensation too high?
Bionet Therapeutics' current Stock Based Compensation is NT$18.9 Mil. Overall, Bionet Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Stock Based Compensation compare to VRTX and REGN?
Bionet Therapeutics' Stock Based Compensation of NT$18.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bionet Therapeutics and its competitors. Bionet Therapeutics's current Stock Based Compensation is NT$18.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Stock Based Compensation of NT$18.9 Mil. The current Stock Based Compensation is NT$18.9 Mil. Bionet Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Stock Based Compensation is NT$18.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionet Therapeutics Business Description

Address No.28, Lane. 36 , Xinhu 1st Road, 1st Floor, Neihu District, Taipei, TWN, 11497
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
20GF Score

Get the complete analysis for ROCO:7808

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.80
Price